5-amino-1mq purity (5-Amino-1-Methylquinolinium Chloride) – 98%+ – 5g 5-Amino-1MQ Peptide - 10mg

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

To browse Loti Labs : Please log in or create an account

Side effect tolerance Temporary digestive symptoms can occur as the body adjusts to treatment

Inject the medication slowly and steadily

Clinical trials showed modest fat loss of roughly 2-3 kg over 12 weeks, and the compound was never approved as a pharmaceutical because efficacy did not meet the threshold for drug registration (Heffernan et al., 2001)